Relmada Therapeutics (RLMD) Return on Sales (2012 - 2013)
Relmada Therapeutics (RLMD) reported Return on Sales of 0.08% for Q4 2013, down 4.0% year-over-year from 0.08% in Q4 2012, and down 22.05% quarter-over-quarter from 0.06% in Q3 2013.
Relmada Therapeutics (RLMD) Return on Sales (2012 - 2013) Analysis & Trends
Relmada Therapeutics (RLMD) has 2 years of Return on Sales data on file, last reported at 0.08% in Q4 2013.
- Return on Sales for Q4 2013 came in at 0.08%, down 4.0% year-over-year; the trailing twelve-month figure through Nov 2013 was 0.08% (changed N/A YoY), and the FY2013 annual result was 0.09%, down 7.0% from the prior year.
- Return on Sales retreated to 0.08% in Q4 2013 per RLMD's latest filing, from 0.06% in the prior quarter.
- Over five years, Return on Sales peaked at 0.02% in Q1 2013 and troughed at 0.31% in Q2 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.00% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 0.00% |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 0.00% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Relmada Therapeutics | 581.07 Mn | 581.07 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2013 | -0.08% |
| Aug 31, 2013 | -0.06% |
| May 31, 2013 | -0.31% |
| Feb 28, 2013 | -0.02% |
| Nov 30, 2012 | -0.04% |
| Aug 31, 2012 | -0.06% |
| May 31, 2012 | -0.06% |